Helius Medical Technologies Inc (OTCMKTS:HSDT)’s stock price was down 6% during mid-day trading on Friday . The company traded as low as $2.13 and last traded at $2.20. Approximately 1,941,194 shares changed hands during mid-day trading, an increase of 1,110% from the average daily volume of 160,427 shares. The stock had previously closed at $2.34.
A number of research analysts have weighed in on the stock. BTIG Research reissued a “buy” rating on shares of Helius Medical Technologies in a research report on Monday, March 18th. Oppenheimer assumed coverage on shares of Helius Medical Technologies in a research report on Tuesday, March 5th. They set a “buy” rating and a $10.00 target price for the company.
The business has a 50-day moving average price of $2.59.
A number of institutional investors have recently modified their holdings of the business. Bank of America Corp DE grew its stake in Helius Medical Technologies by 61.6% during the fourth quarter. Bank of America Corp DE now owns 14,279 shares of the company’s stock worth $132,000 after buying an additional 5,443 shares during the last quarter. Polar Capital LLP bought a new stake in Helius Medical Technologies during the fourth quarter worth about $3,664,000. Geode Capital Management LLC grew its stake in Helius Medical Technologies by 47.9% during the fourth quarter. Geode Capital Management LLC now owns 184,087 shares of the company’s stock worth $1,686,000 after buying an additional 59,583 shares during the last quarter. Northern Trust Corp grew its stake in Helius Medical Technologies by 26.4% during the fourth quarter. Northern Trust Corp now owns 204,962 shares of the company’s stock worth $1,877,000 after buying an additional 42,762 shares during the last quarter. Finally, Scotia Capital Inc. bought a new stake in Helius Medical Technologies during the fourth quarter worth about $153,000.
About Helius Medical Technologies (OTCMKTS:HSDT)
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
Featured Article: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.